New Delhi: India’s listed hospitals are likely to keep double-digit revenue growth at the same time as EBITDA margins keep rangebound due to a busy bed-addition cycle, brokerage agency Kotak Securities stated in a analysis report.
With ARPOB growth of 6-14 per cent YoY for many gamers, sturdy Inpatient Division volumes and diagnostics B2C traction selecting up, the brokerage sees top-line momentum holding.
The March quarter was total a “fantastic quarter”, stated Kotak. Hospitals delivered 18 per cent YoY gross sales growth and 16 per cent YoY EBITDA growth. ARPOB growth was wholesome at 6-14 per cent YoY for many hospitals, led by a discount in ALOS and a greater speciality combine. KIMS posted 14 per cent YoY ARPOB growth on contributions from high-ARPOB markets like Thane and Bengaluru.
Accoridng to Kotak Securities analysis report, Medanta’s ARPOB rose 6 per cent YoY regardless of the brand new Noida hospital, aided by decrease ALOS and a better complicated case combine. Apollo Hospitals noticed 9 per cent YoY ARPP growth from higher pricing/case combine plus 7 per cent YoY IP quantity growth. IPD footfalls grew 7-30 per cent YoY for many gamers, besides Narayana Hrudayalaya and Max.
Max Healthcare was the outlier with simply 1 per cent YoY ARPOB growth, hit by discontinuation of high-value chemo medicine for CGHS sufferers and GST fee cuts. Oncology’s share of gross sales dropped to 21 per cent from 26 per cent a 12 months in the past. Excluding oncology, Max’s gross revenues nonetheless grew 15 per cent YoY.
Profitability took a success from new mattress additions. Aside from APHS and Narayana Hrudayalaya, all hospitals raised operational mattress rely by 5-21 per cent YoY. For APHS, operational beds rose just one per cent QoQ, but capability beds jumped 6 per cent QoQ. Losses from 4 new hospitals — Defence Colony, Kolkata, Hyderabad and Pune — had been Rs 414 million in 4QFY26 versus Rs 150 million in 3QFY26. Mature unit EBITDA margin was 25.5 per cent, up from 24.4 per cent YoY. KIMS and Medanta margins had been additionally pressured by Thane/Bengaluru and Noida models, with KIMS going through delays in insurance coverage empanelment.
Diagnostics inside protection fared nicely. DLPL and Metropolis reported 15-17 per cent YoY natural gross sales growth on 9-13 per cent YoY pattern quantity growth and a better wellness combine. B2C traction improved as on-line gamers lower reductions. Metropolis’ 23 per cent YoY gross sales growth was boosted by Core, DAPIC, Scientific and Ambika acquisitions. Cumulative EBITDA for diagnostics grew 27 per cent YoY with 175 bps margin expansion.
Source link
#Hospital #expansion #cycle #margins #rangebound #revenue #growth #trend #maintain #Kotak #Securities
